

Esco, Nuvonis enter into MoU to support novel vaccines in Asia

04 October 2018 | News

Both companies will also forge a commercial partnership to deliver domestic vaccine production capacity to support pandemic preparedness and emergency responsiveness.



Singapore - Esco Aster (Singapore) and Nuvonis Technologies (Austria) will sign a Memorandum of Understanding (MoU) for the early development and manufacturing of viral vaccines prevalent in Asia.

Esco Aster's proprietary Tide Motion bioreactors will be partnered with Nuvonis's state-of-the-art Vero cell lines and animal component-free cell culture media to develop high yielding manufacturing processes. Innovative downstream purification technology will be used for high product recovery and short processing times.

Both companies will also forge a commercial partnership to deliver domestic vaccine production capacity to support pandemic preparedness and emergency responsiveness.

The MoU leverages Nuvonis' qualified GMP Cell Banks, and Esco Aster's linearly-scalable bioreactors and cGMP-compliant facility to lower cost-of-goods and increase the capacity of vaccine manufacturing platforms. This will make vaccines more accessible and affordable to the Asian population.

"The signing of this MoU is a commitment to explore how both companies can work together to demonstrate collective capabilities capable of enabling a public-private partnership that can improve vaccination programmes," Xiangliang Lin, Esco Aster's Chief Executive Officer.

"We are excited about business opportunities that this partnership will enable. In Esco Aster, we have a partner that has developed highly relevant technology in vaccine manufacturing and therefore strategically fits well to our goal providing optimal manufacturing processes for vaccines on a worldwide scale," Manfred Reiter, Managing Director Nuvonis.